Rockefeller-Born, IPO-Validated Biodefense & Drug Discovery Biotechnology

With failure rates approaching 98% across the pharmaceutical industry, the drug discovery process is in dire need of improvement at every stage. AI-driven discovery remains constrained by the same flawed datasets.

DRUG DISCOVERY | TECHBIO

Once sequencing was automated, the field sequenced the whole genome. Drug discovery is at that inflection, and the bottleneck is the cell: 98% of programs fail because lab cells express distorted targets. Chromovert® is a TRL9 platform building cells that express targets as they exist in the body, across all ~400 GPCRs at once. Screen the family in parallel, pick the indication and candidate last. Biodefense on US soil; commercial discovery exploring China, the fastest route to human trials.

BIODEFENSE | AI-GENERATED WARFARE TOXINS

AI can now design novel neurotoxic agents faster than a defense organized agent by agent can answer them. Synthesis is cheap; recognition is the bottleneck. Secondcell Bio supplies the missing link: a combinatorial array of living cells expressing human receptors as they exist in the CNS, built once and reusable against every future agent. An unknown sample is profiled on arrival and matched to an FDA-approved countermeasure in days. Chromovert® is TRL9, proven by $150M in customer-funded R&D.

CONTACT | kambiz.shekdar@secondcellbio.com